Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

Keyphrases

• Placebo 100%
• Meta-analysis 100%
• Systematic Meta-analysis 100%
• Psoriatic Arthritis 100%
• T Helper 17 (Th17) 100%
• Randomized Controlled Clinical Trial 100%
• Relative Risk 75%
• Placebo-controlled 50%
• Randomized Controlled Trial 50%
• Serious Adverse Events 50%
• Infection Risk 50%
• Treatment Discontinuation 50%
• TNF-α Antagonists 50%
• Th17 Pathway 50%
• Disease Activity 25%
• Adverse Events 25%
• Tolerability 25%
• Scopus 25%
• Quality Assessment 25%
• Cochrane 25%
• Risk of Bias Tool 25%
• Mechanism of Action 25%
• Random Effects Model 25%
• Tuberculosis 25%
• Publication Bias 25%
• Incident Cases 25%
• Increased Incidence 25%
• Biological Agents 25%
• Clinically Meaningful Improvement 25%
• American College of Rheumatology 25%
• Short-term Treatment 25%
• Serious Infection 25%
• Naivety 25%
• Joint Disease 25%
• Active Control 25%
• Pathway Inhibitors 25%
• ACR50 25%
• Disabling Conditions 25%
• Candida Infection 25%
• Acceptable Safety 25%
• ACR20 25%
• Th17 Axis 25%
• Objective Risk 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Psoriatic Arthritis 100%
• Controlled Clinical Trial 100%
• Infection 50%
• Biological Product 50%
• Adverse Event 50%
• Tumor Necrosis Factor 50%
• Randomized Controlled Trial 33%
• Disease Activity 16%
• Arthropathy 16%
• Tolerability 16%
• Random Effects Model 16%
• Diseases 16%